Burning Rock announces the publication of a prospectus in connection with the direct listing on the London Stock Exchange

Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.

NOT TO BROADCAST, PUBLISH OR DISTRIBUTE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR FROM AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE ILLEGAL .

BURNING ROCK BIOTECH LIMITED – Approval and publication of the prospectus

October 27, 2022

This advertisement is an advertisement for the purposes of the prospectus regulations of the Financial Conduct Authority (“FCA”) and is not a prospectus or an offer of securities for sale in any jurisdiction.

Neither this announcement, nor anything contained herein, nor anything in the prospectus (the “Prospectus”) referred to herein shall form the basis of, or be relied upon in connection with, any offer or undertaking in any jurisdiction. Investors should not subscribe for or purchase the securities mentioned in this press release except solely on the basis of the information contained in the Prospectus, including the risk factors set out therein, published in connection with the admission (the “Admission”) of the shares of the Company. American Depositary Shares (the “ADS”) to the standard listing segment of the FCA Official List and to trading on the main market of the London Stock Exchange plc (the “LSE”) through a direct listing (the “Direct Listing”).

LONDON, Oct. 27, 2022 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on applying next-generation sequencing technology ( NGS) in the field of precision oncology, announces that, following its announcement on October 21, 2022, a Prospectus dated today has been approved by the FCA for Admission and Direct Listing.

A copy of the Prospectus has been submitted to the FCA’s National Storage Mechanism and will be available for inspection at the following link: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

A copy of the Prospectus will also be available online on the Company’s website at http://ir.brbiotech.com.

The Burning Rock ADSs will continue to be listed and traded on the Nasdaq Global Market, such ADSs being fully fungible with the LSE-listed ADSs. Custody and depositary links will be established between Euroclear, Clearstream and DTC to facilitate cross-market transfers of ADS associated with secondary market trading.

Admission and direct registration is expected to be effective on or about November 1, 2022 at 8:00 a.m. (London time). Trading of ADSs on the LSE under the symbol “BNR” will begin at the same time.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to protect life through science, focuses on the application of next-generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection tests for advanced-stage cancer patients, and ii) early cancer detection, which has moved from proof-of-concept R&D to clinical validation step.

For more information on Burning Rock, please visit: www.brbiotech.com.

Requests:

Contact: [email protected]

Annex1

The following tables present the consolidated capitalization and unaudited indebtedness of the Company as of August 31, 2022 (USD, thousands).

There has been no significant change in the capitalization of the Group since August 31, 2022.

The following tables show the Group’s net debt as of August 31, 2022 (USD, thousands).

There are no contingent or indirect liabilities.

Other Updates

There has been no significant change in the Group’s debt since August 31, 2022.

Important legal information

The information in this announcement is provided for informational purposes only and does not purport to be comprehensive or complete, and this announcement does not constitute or form part of an invitation or inducement to engage in investment activity. No reliance can be placed by anyone for any purpose on the information contained in this announcement or on its accuracy, fairness or completeness. The content of this announcement should not be construed as legal, financial or tax advice.

This announcement is not intended for broadcast, publication or distribution, directly or indirectly, in Australia, Canada, South Africa or Japan or in any other jurisdiction where, or to anyone to whom, doing so would constitute violation of applicable law. or regulations.

These materials do not constitute or form part of any offer or invitation to sell or issue, nor any solicitation of any offer to purchase or subscribe for, ADS or any other security, nor (or any part thereof -it), or the fact of its distribution, form the basis of, or be invoked in connection with, any contract therefor.

This announcement may include forward-looking statements, which are based on current expectations and projections of future events. Such statements may include, but are not limited to, any statement preceded, followed by, or including words such as “target”, “believe”, “expect”, “aim”, “intend”, ” can”, “anticipate”, “estimate”. “, “plan”, “project”, “will”, “may have”, “probable”, “should”, “would”, “could” and any other word or term having a similar meaning or its negative form. These forward-looking statements are subject to risks, uncertainties and assumptions about Burning Rock and its subsidiaries. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements may not occur. Past performance cannot be taken as an indication of future performance and should not be taken as a representation that the trends or activities underlying past performance will continue in the future. No representation or warranty is or will be made that any forward-looking statement will occur. The forward-looking statements contained in this announcement speak only as of the date of this announcement.

Burning Rock expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statements contained in this announcement and disclaims any obligation to update its view of the risks or uncertainties described herein or to publicly announce the results of any revisions to forward-looking statements. – forward-looking statements made in this announcement, whether as a result of new information, future developments or otherwise, except as required by law.

The information in this announcement is subject to change. Persons viewing this announcement should ensure that they fully understand and accept the risks set out in the Prospectus.

Unless otherwise stated, market, industry and competitive position data are estimates (and therefore, approximate) and should be treated with caution. This information has not been independently audited or verified, and the Group has not verified the underlying economic assumptions on which it is based. Certain data in this announcement, including financial, statistical and operational information, has been rounded. Due to rounding, the totals of the data presented in this announcement may differ slightly from the actual arithmetic totals of these data.

For the avoidance of doubt, material from the Company’s website is not incorporated by reference into, and does not form part of, this announcement.

____________________________1 Text included in the Prospectus.

Source: Burning Rock Biotech Limited